Table 5. Tattoo-associated acquired epidermodysplasia verruciformis: epidemiology features.

A, age (years); C, case; G, gender; HT, human papillomavirus testing; M, man; Na, nationality; NS, not stated; PT, professional tattoo; Ref, reference; Sp, Spain; TD, tattoo duration (number of years after tattoo placement that acquired epidermodysplasia verruciformis lesions appeared); US, United States; +, positive or present.

^aHuman immunodeficiency virus was diagnosed eight months prior to presentation of the acquired epidermodysplasia verruciformis. He has a medical history of cystic fibrosis, eczema, and genital molluscum contagiosum.

^bHe presented with four months duration of redness, dryness, and pruritus at the tattoo periphery; the duration of time between acquiring the tattoo and the onset of the erythematous, eczematous linear plaques of acquired epidermodysplasia verruciformis was not stated.

C	A	Na	G	Human immunodeficiency virus	HT	PT	TD	Ref
1	29	US	M	+a; CD4 count: 42 cells/mm3 (reference range, 500-1,200 cells/mm3); Viral load: 2,388 copies/ml (reference range, 20-10,000,000 copies/ml)	NS	NS	NSb	[19]
2	44	Sp	M	+; + antiretroviral treatment; Viral load: irregular control	NS	NS	NS	[20]